No Data
No Data
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Celldex Therapeutics Initiated at Overweight by Morgan Stanley
Morgan Stanley Initiates Celldex Therapeutics(CLDX.US) With Buy Rating, Announces Target Price $46
Celldex Therapeutics Insiders Sold US$2.1m Of Shares Suggesting Hesitancy
Celldex Therapeutics to Present at Upcoming Investor Conferences
Atopic Dermatitis: 2025 Pipeline Insights Report Covering 100+ Companies and 120+ Pipeline Drugs, Including ICP-332 (Innocare Pharma), APG777 (Apogee Therapeutics), and Barzolvolimab (Celldex Therapeutics)